Literature DB >> 22855503

T cell signaling targets for enhancing regulatory or effector function.

Fan Pan1, Huimin Fan, Zhongmin Liu, Shuiping Jiang.   

Abstract

To respond to infection, resting or naïve T cells must undergo activation, clonal expansion, and differentiation into specialized functional subsets of effector T cells. However, to prevent excessive or self-destructive immune responses, regulatory T cells (T(regs)) are instrumental in suppressing the activation and function of effector cells, including effector T cells. The transcription factor Forkhead box P3 (Foxp3) regulates the expression of genes involved in the development and function of T(regs). Foxp3 interacts with other transcription factors and with epigenetic elements such as histone deacetylases (HDACs) and histone acetyltransferases. T(reg) suppressive function can be increased by exposure to HDAC inhibitors. The individual contributions of different HDAC family members to T(reg) function and their respective mechanisms of action, however, remain unclear. A study showed that HDAC6, HDAC9, and Sirtuin-1 had distinct effects on Foxp3 expression and function, suggesting that selectively targeting HDACs individually or in combination may enhance T(reg) stability and suppressive function. Another study showed that the receptor programmed death 1 (PD-1), a well-known inhibitor of T cell activation, halted cell cycle progression in effector T cells by inhibiting the transcription of the gene encoding the substrate-recognition component (Skp2) of the ubiquitin ligase SCF(Skp2). Together, these findings reveal new signaling targets for enhancing T(reg) or effector T cell function that may be helpful in designing future therapies, either to increase T(reg) suppressive function in transplantation and autoimmune diseases or to block PD-1 function, thus increasing the magnitude of antiviral or antitumor immune responses of effector T cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855503      PMCID: PMC4659372          DOI: 10.1126/scisignal.2003364

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  28 in total

1.  FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression.

Authors:  Bin Li; Arabinda Samanta; Xiaomin Song; Kathryn T Iacono; Kathryn Bembas; Ran Tao; Samik Basu; James L Riley; Wayne W Hancock; Yuan Shen; Sandra J Saouaf; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-07       Impact factor: 11.205

2.  Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation.

Authors:  Petra Hoffmann; Tina J Boeld; Ruediger Eder; Jochen Huehn; Stefan Floess; Georg Wieczorek; Sven Olek; Wolfgang Dietmaier; Reinhard Andreesen; Matthias Edinger
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

Review 3.  Regulatory T cells exert checks and balances on self tolerance and autoimmunity.

Authors:  Kajsa Wing; Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2009-12-17       Impact factor: 25.606

Review 4.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

5.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

6.  CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.

Authors:  Richard V Parry; Jens M Chemnitz; Kenneth A Frauwirth; Anthony R Lanfranco; Inbal Braunstein; Sumire V Kobayashi; Peter S Linsley; Craig B Thompson; James L Riley
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

7.  Deacetylase inhibition promotes the generation and function of regulatory T cells.

Authors:  Ran Tao; Edwin F de Zoeten; Engin Ozkaynak; Chunxia Chen; Liqing Wang; Paige M Porrett; Bin Li; Laurence A Turka; Eric N Olson; Mark I Greene; Andrew D Wells; Wayne W Hancock
Journal:  Nat Med       Date:  2007-10-07       Impact factor: 53.440

8.  First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.

Authors:  Piotr Trzonkowski; Maria Bieniaszewska; Jolanta Juścińska; Anita Dobyszuk; Adam Krzystyniak; Natalia Marek; Jolanta Myśliwska; Andrzej Hellmann
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

9.  Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.

Authors:  M Asano; M Toda; N Sakaguchi; S Sakaguchi
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  7 in total

1.  KEAP1 Editing Using CRISPR/Cas9 for Therapeutic NRF2 Activation in Primary Human T Lymphocytes.

Authors:  Sanjeev Noel; Sul A Lee; Mohanraj Sadasivam; Abdel R A Hamad; Hamid Rabb
Journal:  J Immunol       Date:  2018-01-19       Impact factor: 5.422

Review 2.  Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.

Authors:  Manuela Terranova-Barberio; Scott Thomas; Pamela N Munster
Journal:  Immunotherapy       Date:  2016-06       Impact factor: 4.196

Review 3.  Anti-inflammatory therapy in chronic disease: challenges and opportunities.

Authors:  Ira Tabas; Christopher K Glass
Journal:  Science       Date:  2013-01-11       Impact factor: 47.728

4.  Histone deacetylation of memory T lymphocytes by You-Gui-Wan alleviates allergen-induced eosinophilic airway inflammation in asthma.

Authors:  Hong Ping Zhang; Juan Juan Fu; Tao Fan; Wen Bin Zhang; Zeng Li Wang; Lei Wang; Gang Wang
Journal:  Chin Med       Date:  2015-05-13       Impact factor: 5.455

Review 5.  Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.

Authors:  Roberta Mazzone; Clemens Zwergel; Antonello Mai; Sergio Valente
Journal:  Clin Epigenetics       Date:  2017-05-30       Impact factor: 6.551

6.  Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.

Authors:  Aravindhan Ganesan; Marawan Ahmed; Isobel Okoye; Elena Arutyunova; Dinesh Babu; William L Turnbull; Joydeb Kumar Kundu; Justin Shields; Katharine Cheryl Agopsowicz; Lai Xu; Yasser Tabana; Nutan Srivastava; Guangzhi Zhang; Tae Chul Moon; Alexandr Belovodskiy; Mostofa Hena; Appan Srinivas Kandadai; Seyedeh Nargess Hosseini; Mary Hitt; John Walker; Michael Smylie; Frederick G West; Arno G Siraki; M Joanne Lemieux; Shokrollah Elahi; James A Nieman; D Lorne Tyrrell; Michael Houghton; Khaled Barakat
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

7.  Prenatal high-dose vitamin D3 supplementation has balanced effects on cord blood Th1 and Th2 responses.

Authors:  Evana Akhtar; Akhirunnesa Mily; Ahsanul Haq; Abdullah Al-Mahmud; Shams El-Arifeen; Abdullah Hel Baqui; Daniel E Roth; Rubhana Raqib
Journal:  Nutr J       Date:  2016-08-09       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.